16例再生障碍性贫血患者的异基因造血干细胞移植
[Allogeneic hematopoietic stem cell transplantation for 16 patients with aplastic anemia].
作者信息
Zhai Wei-Hua, Wang Mei, Zhou Zheng, Zhai Wen-Jing, Zhang Rong-Li, Wang Hua, Song A-Xia, Feng Si-Zhou, Han Ming-Zhe
机构信息
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2007 Feb;28(2):78-82.
OBJECTIVE
To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA).
METHODS
Twelve patients with severe AA (SAA) and 4 with chronic AA (CAA) received allo- HSCT. The effectiveness and complication were analyzed retrospectively.
RESULTS
Hematopoiesis reconstitution was achieved 14 patients (87.50%). The median time of neutrophils reached to 0.5 x 10(9)/L and platelets reached to 20 x 10(9)/L were 14 (11 - 16) and 14 (10 - 33) days, respectively. Six cases developed grade I - II acute graft-versus-host disease (aGVHD), chronic local GVHD occurred in 2 patients. Graft rejection occurred in 3 cases. Thirteen cases survived with a median of 10 (0.5 - 84) months at the end of follow-up. Three cases died of un-engraftment, graft rejection (GR) and interstitial pneumonia (IP) each.
CONCLUSION
Allo-HSCT is an effective therapy for patients with AA. Enhancing immunosuppressive treatment for conditioning and GVHD prophylaxis may reduce the incidence of GR and GVHD.
目的
评估异基因造血干细胞移植（allo-HSCT）治疗再生障碍性贫血（AA）的疗效。
方法
12例重型再生障碍性贫血（SAA）患者和4例慢性再生障碍性贫血（CAA）患者接受了allo-HSCT。对疗效和并发症进行回顾性分析。
结果
14例患者（87.50%）实现造血重建。中性粒细胞计数达到0.5×10⁹/L和血小板计数达到20×10⁹/L的中位时间分别为14（11 - 16）天和14（10 - 33）天。6例发生Ⅰ - Ⅱ级急性移植物抗宿主病（aGVHD），2例发生慢性局限性GVHD。3例发生移植物排斥反应。随访结束时，13例患者存活，中位生存期为10（0.5 - 84）个月。3例分别死于植入失败、移植物排斥反应（GR）和间质性肺炎（IP）。
结论
allo-HSCT是治疗AA患者的有效方法。加强预处理的免疫抑制治疗和预防GVHD可能降低GR和GVHD的发生率。
Zotero 插件